Zoetis Inc. $ZTS Position Cut by Vontobel Holding Ltd.

Key Points

• Vontobel Holding Ltd. reduced its stake in Zoetis Inc. by 5.7%, selling 97,028 shares, which brought its ownership to 1,602,019 shares valued at approximately $249.8 million.
• Analyst ratings for Zoetis have been mixed, with firms like Leerink Partners and Stifel Nicolaus downgrading their ratings in recent months, while Argus maintains a buy rating with a target price of $190.00.
• Zoetis reported earnings of $1.76 per share for the last quarter, surpassing estimates, with revenue of $2.46 billion, reflecting a 4.2% year-over-year increase.

Vontobel Holding Ltd. trimmed its holdings in Zoetis Inc. (NYSE:ZTS - Free Report) by 5.7% in the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 1,602,019 shares of the company's stock after selling 97,028 shares during the quarter. Vontobel Holding Ltd. owned about 0.36% of Zoetis worth $249,835,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also added to or reduced their stakes in ZTS. Lindbrook Capital LLC raised its holdings in shares of Zoetis by 1.8% during the first quarter. Lindbrook Capital LLC now owns 3,715 shares of the company's stock worth $612,000 after acquiring an additional 65 shares in the last quarter. Scott & Selber Inc. increased its position in Zoetis by 0.6% during the second quarter. Scott & Selber Inc. now owns 11,652 shares of the company's stock worth $1,817,000 after buying an additional 67 shares during the last quarter. Secure Asset Management LLC increased its position in Zoetis by 2.9% during the second quarter. Secure Asset Management LLC now owns 2,448 shares of the company's stock worth $382,000 after buying an additional 68 shares during the last quarter. Quotient Wealth Partners LLC increased its position in Zoetis by 2.3% during the first quarter. Quotient Wealth Partners LLC now owns 3,167 shares of the company's stock worth $521,000 after buying an additional 72 shares during the last quarter. Finally, Menard Financial Group LLC increased its position in Zoetis by 3.8% during the first quarter. Menard Financial Group LLC now owns 2,032 shares of the company's stock worth $305,000 after buying an additional 75 shares during the last quarter. 92.80% of the stock is owned by institutional investors.

Analyst Ratings Changes

Several research firms have commented on ZTS. Leerink Partnrs downgraded shares of Zoetis from a "strong-buy" rating to a "hold" rating in a research report on Thursday, July 17th. Weiss Ratings reissued a "hold (c-)" rating on shares of Zoetis in a research report on Wednesday. Stifel Nicolaus downgraded shares of Zoetis from a "buy" rating to a "hold" rating and lowered their target price for the stock from $165.00 to $160.00 in a research report on Wednesday, June 18th. Leerink Partners downgraded shares of Zoetis from an "outperform" rating to a "market perform" rating and lowered their target price for the stock from $180.00 to $155.00 in a research report on Thursday, July 17th. Finally, Argus reissued a "buy" rating and set a $190.00 target price on shares of Zoetis in a research report on Tuesday, September 9th. Five analysts have rated the stock with a Buy rating and five have given a Hold rating to the company. According to MarketBeat.com, the company currently has a consensus rating of "Moderate Buy" and an average target price of $200.88.

Zoetis Stock Up 0.6%

ZTS stock opened at $143.61 on Thursday. Zoetis Inc. has a twelve month low of $139.34 and a twelve month high of $196.55. The company has a market cap of $63.65 billion, a PE ratio of 24.72, a price-to-earnings-growth ratio of 2.29 and a beta of 0.90. The business's 50-day simple moving average is $149.41 and its 200 day simple moving average is $154.74. The company has a quick ratio of 1.04, a current ratio of 1.76 and a debt-to-equity ratio of 1.05.

Zoetis (NYSE:ZTS - Get Free Report) last released its earnings results on Tuesday, August 5th. The company reported $1.76 earnings per share for the quarter, topping analysts' consensus estimates of $1.62 by $0.14. Zoetis had a return on equity of 56.90% and a net margin of 27.83%.The business had revenue of $2.46 billion for the quarter, compared to the consensus estimate of $2.41 billion. During the same period last year, the business earned $1.56 earnings per share. The firm's revenue for the quarter was up 4.2% compared to the same quarter last year. Zoetis has set its FY 2025 guidance at 6.300-6.400 EPS. On average, research analysts anticipate that Zoetis Inc. will post 6.07 earnings per share for the current year.

Zoetis Company Profile

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.

Want to see what other hedge funds are holding ZTS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Zoetis Inc. (NYSE:ZTS - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.